This reports provides a data-driven overview of the current and future competitive landscape in FRDA therapeutics.
More than 54,000 diagnosed prevalent cases of FRDA are anticipated in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FRDA.
The marketed drugs space for FRDA is limited to just two approved drugs, Biogen's Skyclarys (omaveloxolone) is the leading drug in FRDA space.
R&D efforts in the FRDA space are limited, with no pre-registration drugs currently in the pipeline and only one molecule in Phase III.
The US is emerging as the key country for conducting FRDA trials.
In North America, partnerships were the most common type of deal among companies developing treatments for FRDA. In Europe, licensing agreements were prevalent.
Scope
GlobalData’s FRDA: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the FRDA market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global FRDA market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Report Scope
Abbreviations
Key Findings
Disease Overview
Disease Etiology
Epidemiology Overview
Epidemiology Overview - Diagnosed Prevalent Cases of FRDA in 2024 and 2029
Treatment Overview
Treatment Guidelines
Management Algorithm - FRDA
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in FRDA
Marketed Drug Profile - Biogen's Skyclarys
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Cost of Therapy
Marketed Drugs - Time to Pricing for Skyclarys
Pipeline Drugs Assessment
Pipeline Drugs Overview - Late-Stage Pipeline Drugs in FRDA
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in CNS
Clinical Trials Assessment
Clinical Trials in FRDA - Historical Overview
Clinical Trials in FRDA - Overview by Phase
Clinical Trials in FRDA - Overview by Status
Clinical Trials in FRDA - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in FRDA - Trials with a Virtual Component
Clinical Trials in FRDA - Geographic Overview
Clinical Trials in FRDA - Single-Country and Multinational Trials by Region
Clinical Trials in FRDA - Top Sponsors with Breakdown by Phase
Clinical Trials in FRDA - Top Sponsors with Breakdown by Status
Clinical Trials in FRDA - Overview by Endpoint Status
Clinical Trials in FRDA - Overview by Race and Ethnicity